Summary
AbbVie Inc. (ABBV) filed an amendment to its Current Report on Form 8-K on May 13, 2020, to provide previously omitted financial statements and pro forma information related to its acquisition of Allergan plc. This filing confirms the completion of the acquisition, which closed on May 8, 2020, making Allergan a wholly-owned subsidiary of AbbVie. The amendment includes Allergan's historical financial statements for the years ended December 31, 2019, 2018, and 2017, as well as unaudited financials for the three months ended March 31, 2020 and 2019. Additionally, it provides unaudited pro forma condensed combined financial information, presenting a combined view of AbbVie and Allergan as if the acquisition had occurred at earlier specified dates. Investors should review these financial statements to understand the historical performance of Allergan and the potential combined financial impact on AbbVie.
Key Highlights
- 1AbbVie Inc. has completed its acquisition of Allergan plc, with Allergan now operating as a wholly-owned subsidiary.
- 2This 8-K/A filing provides crucial historical financial statements for Allergan, covering periods up to December 31, 2019, and unaudited financials for Q1 2020 and Q1 2019.
- 3The report includes unaudited pro forma condensed combined financial information, offering insight into the potential financial performance and position of the combined entity.
- 4The acquisition was officially completed on May 8, 2020, following the original transaction agreement from June 25, 2019.
- 5The pro forma financial information is presented for informational purposes and is not necessarily indicative of future results.
- 6Key exhibits include Allergan's audited financial statements, unaudited interim financial statements, and the pro forma combined financial information.